BGMS — Stock Film
STOCK FILMSCENE 1/11BGMS · $0.78
Stock Expert AI presents
BGMS
Bio Green Med Solution, Inc
~4 min film100% real numbers0 jargon
WHAT DOES THIS COMPANY DO?
Bio Green Med Solution, Inc. A quick introduction.

On the stock market since 2025, it operates in the world of health and science. It has 12 employees. Now — the numbers.

on the stock market since 2025
12 employees
$1.7M market value
Revenue last year:
$0
The loss that same year:
$0
For every $1 it earns, the company spends $5.

The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.

THE SALES TREND
The sales picture, year by year.

Red columns mark years that ended in a loss.

$0
2021
$0
2022
$420K
2023
$43K
2024
$747K
2025
In the vault right now:
$0
DEBT: $2K
At this pace, that money lasts about 1.2 years.

Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.

INSIDE THE REPORT CARD

We compared this company with its own sector across five subjects.

A score of 50 means class average.

BUSINESS QUALITY
12
very weak

Clearly below the class average.

FINANCIAL STRENGTH
55
average

A solid grade overall — yet the debt outweighs the cash. The strength here comes from earnings power.

VALUATION
55
average

The price isn’t cheap next to earnings — that’s why this grade sits in the middle.

GROWTH
68
strong

This grade is a blend: the profit side is strong, the sales tempo slow.

PRICE MOMENTUM
16
very weak

Clearly below the class average.

WORTH WATCHING

Business Quality: Profit power and business quality trail similar companies in the sector.

Price Momentum: The stock has lagged the market in recent months; investor interest is weak right now.

THE COUNCIL REVIEW
9

angles, checked one by one.

The 2 that stand out are on screen; the rest came back neutral.

The council scores out of 10; report-card grades are out of 100.

WEAK SPOTS
The stock has lost its spark0/10
Costs eat into the margin4/10
WORTH WATCHING

Cost Efficiency: As sales grow, profit fails to keep the same pace.

THE FIVE-YEAR JOURNEY
A long and steep decline.

An investor who bought at the very peak is down 87% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.

1
THE BRIGHT SIDE · 1/1
The product is selling

Sales run at $747K a year. A small number, but proof the product has real buyers.

1
THE RISKS · 1/3
Small sales, big loss

A loss of $3.0M against $747K in annual sales.

2
THE RISKS · 2/3
Trading under $1

The stock sits at $0.78. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.

3
THE RISKS · 3/3
The cash has a countdown

At the current pace of spending, the cash lasts about 1.2 years. After that, the company needs to find new money.

FINALE · THE GRADE
F
0 / 100 · MoonshotScore

On our five-subject report card, BGMS sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”

The takeaway: BGMS is a high-risk stock — not yet profitable, and its future rides on its product catching on.

The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.

What would you like to do next?
Open the stock page →
This was a film — not investment advice.
Data: FMP & company filings
Jul 21, 2026 · stockexpertai.com · Stock Film